US20050100564A1 - Controlled release delivery system for nasal applications - Google Patents

Controlled release delivery system for nasal applications Download PDF

Info

Publication number
US20050100564A1
US20050100564A1 US10/772,964 US77296404A US2005100564A1 US 20050100564 A1 US20050100564 A1 US 20050100564A1 US 77296404 A US77296404 A US 77296404A US 2005100564 A1 US2005100564 A1 US 2005100564A1
Authority
US
United States
Prior art keywords
weight
formulation
formulation according
oil
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/772,964
Other languages
English (en)
Inventor
Claudia Mattern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mattern Pharma AG
Precisiobiotix Technologies Inc
Udo Mattern
Original Assignee
Udo Mattern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Udo Mattern filed Critical Udo Mattern
Assigned to MATTERN, UDO reassignment MATTERN, UDO ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MATTERN, CLAUDIA
Publication of US20050100564A1 publication Critical patent/US20050100564A1/en
Priority to US11/560,187 priority Critical patent/US20070149454A1/en
Assigned to M & P PATENT AKTIENGESELLSCHAFT, C/O FUNDATIONSANSTALT reassignment M & P PATENT AKTIENGESELLSCHAFT, C/O FUNDATIONSANSTALT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MATTERN, UDO
Priority to US12/796,165 priority patent/US20100311707A1/en
Priority to US13/194,853 priority patent/US8784882B2/en
Priority to US13/194,928 priority patent/US8574622B2/en
Priority to US13/316,494 priority patent/US8877230B2/en
Priority to US13/547,774 priority patent/US8784869B2/en
Assigned to MATTERN PHARMA AG reassignment MATTERN PHARMA AG MERGER (SEE DOCUMENT FOR DETAILS). Assignors: M & P PATNT AKTIENGESELLSCHAFT
Assigned to MATTERN PHARMA AG reassignment MATTERN PHARMA AG CORRECTIVE ASSIGNMENT TO CORRECT THE TO CORRECT THE ASSIGNOR FROM M & P PATNT AKTIENGESELLSCHAFT TO M & P PATENT AKTIENGESELLSCHAFT PREVIOUSLY RECORDED ON REEL 032291 FRAME 0349. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER EFFECTIVE 02/04/2014. Assignors: M & P PATENT AKTIENGESELLSCHAFT
Priority to US14/322,319 priority patent/US9238072B2/en
Priority to US14/965,137 priority patent/US9579280B2/en
Priority to US15/403,627 priority patent/US9962394B2/en
Assigned to ACERUS PHARMACEUTICALS SRL reassignment ACERUS PHARMACEUTICALS SRL RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: MIDCAP FUNDING V TRUST
Assigned to PRECISIOBIOTIX TECHNOLOGIES INC. reassignment PRECISIOBIOTIX TECHNOLOGIES INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PHAGELUX (CANADA), INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Definitions

  • the present invention relates to a formulation for the controlled release of sexual hormones to the systemic circulation after nasal application.
  • Nasal drug delivery offers many advantages that include rapid adsorption due to abundant capillary vessels, fast onset of action, avoidance of hepatic first-pass metabolism, utility for chronic medication and ease of administration.
  • lipophilic pharmaceutical compounds having a sufficiently low molecular weight in general are readily adsorbed by the mucous membrane of the nose.
  • pharmacokinetic profiles similar to those obtained after intravenous injection.
  • the inventor made intensive studies of various sexual hormone drug formulations and, as a result, surprisingly found that the incorporation of the drug into a special lipophilic or partly lipophilic system not only leads to a higher bioavailability in general caused by sustained serum levels in plasma, but also to a more favourable serum level profile.
  • the invention comprises a formulation for nasal application comprising a) at least one sexual hormone drug; b) at least one lipophilic or partly lipophilic carrier; and c) a compound or a mixture of compounds having surface tension decreasing activity, an amount effective for in situ generation of an emulsion upon contact of the formulation with water.
  • the lipophilic carrier comprises an oil.
  • said oil is a vegetable oil.
  • said oil is castor oil.
  • a preferred embodiment of the invention is characterized in that the amount of oil comprises between 30% and 98% by weight, preferably between 60 and 98% by weight, more preferably between 75% and 95% by weight, even more preferably between 85% and 95% by weight and most preferably around 90% by weight of the formulation.
  • component (c) comprises at least one surfactant selected from the group consisting of lecithin, fatty acid ester of polyvalent alcohols, of sorbitanes, of polyoxyethylensorbitans, of polyoxyethylene, of sucrose, of polyglycerol and/or at least one humectant selected from the group consisting of sorbitol, glycerine, polyethylene glycol, and macrogol glycerol fatty acid ester, or a mixture thereof.
  • surfactant selected from the group consisting of lecithin, fatty acid ester of polyvalent alcohols, of sorbitanes, of polyoxyethylensorbitans, of polyoxyethylene, of sucrose, of polyglycerol and/or at least one humectant selected from the group consisting of sorbitol, glycerine, polyethylene glycol, and macrogol glycerol fatty acid ester, or a mixture thereof.
  • component (c) comprises an oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides.
  • component (c) is comprised within the formulation in an amount of from 1 to 20% by weight, preferably 1 to 10% by weight, more preferably 1 to 5% by weight, and most preferably at around 4% by weight.
  • a further embodiment comprises a viscosity regulating agent.
  • said viscosity regulating agent comprises a thickener or gelling agent selected from the group consisting of cellulose and cellulose derivatives, polysaccharides, carbomers, polyvinyl alcohol, povidone, colloidal silicon dioxide, cetyl alcohols, stearic acid, beeswax, petrolatum, triglycerides and lanolin, or a mixture thereof.
  • a thickener or gelling agent selected from the group consisting of cellulose and cellulose derivatives, polysaccharides, carbomers, polyvinyl alcohol, povidone, colloidal silicon dioxide, cetyl alcohols, stearic acid, beeswax, petrolatum, triglycerides and lanolin, or a mixture thereof.
  • said viscosity increasing agent is colloidal silicon dioxide.
  • the viscosity regulating agent is comprised within the formulation in an amount of from 0.5 to 10% by weight, preferably 0.5 to 5% by weight, more preferably 1 to 3% by weight, and most preferably at around 3% by weight.
  • the sexual hormone drug is testosterone.
  • the sexual hormone drug is comprised within the formulation in an amount of from 0.5 to 6% by weight, preferably 2 to 4% by weight, more preferably 0.5 to 2% by weight, and most preferably at around 2% by weight.
  • FIG. 1 shows the serum levels of free testosterone at baseline and after nasal application of testosterone.
  • the resultant formulation is chemically and physically stable and can be a suspension or a solution of the pharmacologically active substance.
  • it is filled into a preservative-free, airless multi-dose device able to accurately deliver doses of the above formulation, also at higher viscosities.
  • the drug or the drug particles should be efficiently trapped at the deposition site and be absorbed at a predictable rate across the mucous membrane of the patient, thereby limiting possible deactivation by metabolizing enzymes and/or protein-binding.
  • the term “sexual hormone drug” shall mean at least one sexual hormone (such as testosterone) or at least one biologic pro-drug of a sexual hormone (such as androstenedione, progesterone, 17- ⁇ -hydroxyprogesterone) or at least one derivative of a sexual hormone (such as mestanolone and 4-chloro-1-dehydromethyltestosterone) or a combination thereof.
  • the sexual hormone drug is testosterone.
  • the sexual hormone drug is comprised within the formulation in an amount of from 0.5 to 6% by weight, preferably 2 to 4% by weight, more preferably 0.5 to 2% by weight, and most preferably at around 2% by weight.
  • the drug of this invention may be introduced into the formulation also in a processed form such as microspheres, liposomes etc.
  • lipophilic carrier shall comprise, but not limited to, a vegetable oil such as castor oil, soybean oil, sesame oil or peanut oil, fatty acid ester such as ethyl- and oleyloleat, isopropylmyristate, medium chain triglycerides, glycerol esters of fatty acids, or polyethylene glycol, phospholipids, white soft paraffin, or hydrogenated castor oil. Particularly useful is castor oil.
  • the incorporation of the drug is also possible into an oil mixture.
  • the lipophilic part can be present in a formulation in an amount between 30% and 98% by weight, preferably between 60 and 98% by weight, more preferably between 75% and 95% by weight, even more preferably between 85% and 95% by weight and most preferably around 90% by weight of the formulation.
  • Componentn (C) shall comprise at least a surfactant such as, but not limited to, lecithin, fatty acid ester of polyvalent alcohols, of sorbitanes, of polyoxyethylensorbitans, of polyoxyethylene, of sucrose, of polyglycerol and/or at least one humectant such as sorbitol, glycerine, polyethylene glycol, or macrogol glycerol fatty acid ester.
  • a surfactant such as, but not limited to, lecithin, fatty acid ester of polyvalent alcohols, of sorbitanes, of polyoxyethylensorbitans, of polyoxyethylene, of sucrose, of polyglycerol and/or at least one humectant such as sorbitol, glycerine, polyethylene glycol, or macrogol glycerol fatty acid ester.
  • oleoyl macrogolglycerides such as Labrafil M 1944 CS, as available from G
  • the incorporation of the drug is also possible into a surfactant mixture.
  • the particular amount of surfactant that constitutes an effective amount is dependent on the particular oil or oil mixture (see above) used in the formulation. It is therefore not practical to enumerate specific amounts for use with specific formulations of the invention. Generally, however, the surfactant can be present in a formulation in an amount of from 1 to 20% by weight, preferably 1 to 10% by weight, more preferably 1 to 5% by weight, and most preferably at around 4% by weight.
  • viscosity regulating agent shall mean a thickener or gelling agent.
  • examples are, but not limited to, cellulose and derivatives thereof, polysaccharides, carbomers, polyvinyl alcohol, povidone, colloidal silicon dioxide, cetyl alcohols, stearic acid, beeswax, petrolatum, triglycerides or lanolin.
  • colloidal silicon dioxide such as Acrosil 200, as availble from Degussa).
  • the incorporation of the drug is also possible into a mixture of thickeners or gelling agents.
  • thickener/gelling agent(s) can be present in a formulation in an amount from 0.5 to 10% by weight, preferably 0.5 to 5% by weight, more preferably 1 to 3% by weight, and most preferably at around 3% by weight.
  • the formulation according to this invention may also be processed into powder form, e.g. by lyophilization or spray-drying.
  • formulations of the invention can be prepared very easily by conventional methods, i.e.:
  • the thickener or gelling agent is added to a sufficient amount of water and dispersed with high speed mixing and, if necessary, a surfactant (mixture 1).
  • a surfactant mixture 1
  • water and/or the lipophilic carrier are introduced and, if necessary, a surfactant (mixture 2).
  • mixture 2 the hormone is added very carefully avoiding introducing air.
  • Mixture 2 is added to mixture 1, if necessary pH and tonicity are adjusted and the final mixture is homogenised and sterilised.
  • Lipophilic carrier and emulsifier are filled into a stirrer vessel and about 75% of the viscosity regulating agent is mixed in.
  • the hormone is added under stirring until a homogenous dispersion of the active ingredient is obtained. Then the formulation is adjusted to the necessary viscosity with the rest of the viscosity regulating agent.
  • the formulation is preferably filled into a preservative-free, airless nasal spray device such as the COMOD system available from Ursatec.
  • “higher availability” is meant that after a single application a serum level of sexual hormone significantly higher than baseline is maintained for 6 hours, more preferably for 8 hours and most preferably for at least 10 hours.
  • the release of the hormone is sustained due to its solubility in the oily carrier and to the viscosity of the formulation remaining on the mucous membrane for a prolonged duration of time.
  • the dotted line shows the serum level after application of 1 spray per nostril once of the most preferred formulation (see Table 1).
  • the formulation for nasal application of this invention is different from conventional formulations, especially to those for sustained release, as it is mimicking the physiologic daily rhythm of testosterone release. It is also avoiding supra- and sub-normal testosterone levels, which is pleasant for the patient and a demand for hormone replacement therapy. As shown in FIG. 1 (upper line), a simple nasal spray containing testosterone is unsatisfactory in this sense.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
US10/772,964 2003-11-11 2004-02-04 Controlled release delivery system for nasal applications Abandoned US20050100564A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US11/560,187 US20070149454A1 (en) 2003-11-11 2006-11-15 Controlled Release Delivery System for Nasal Applications and Method of Treatment
US12/796,165 US20100311707A1 (en) 2003-11-11 2010-06-08 Controlled release delivery system for nasal applications and methods of treatment
US13/194,853 US8784882B2 (en) 2003-11-11 2011-07-29 Controlled release delivery system for nasal applications and method of treatment
US13/194,928 US8574622B2 (en) 2003-11-11 2011-07-30 Controlled release delivery system for nasal applications
US13/316,494 US8877230B2 (en) 2003-11-11 2011-12-10 Controlled release delivery system for nasal applications
US13/547,774 US8784869B2 (en) 2003-11-11 2012-07-12 Controlled release delivery system for nasal applications and methods of treatment
US14/322,319 US9238072B2 (en) 2003-11-11 2014-07-02 Controlled release delivery system for nasal applications and method of treatment
US14/965,137 US9579280B2 (en) 2003-11-11 2015-12-10 Controlled release delivery system for nasal applications and method of treatment
US15/403,627 US9962394B2 (en) 2003-11-11 2017-01-11 Controlled release delivery system for nasal applications and method of treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025769.5 2003-11-11
EP03025769A EP1530965B1 (de) 2003-11-11 2003-11-11 Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US11/560,187 Continuation US20070149454A1 (en) 2003-11-11 2006-11-15 Controlled Release Delivery System for Nasal Applications and Method of Treatment
US11/560,187 Continuation-In-Part US20070149454A1 (en) 2003-11-11 2006-11-15 Controlled Release Delivery System for Nasal Applications and Method of Treatment
US13/194,928 Continuation US8574622B2 (en) 2003-11-11 2011-07-30 Controlled release delivery system for nasal applications
US13/547,774 Continuation-In-Part US8784869B2 (en) 2003-11-11 2012-07-12 Controlled release delivery system for nasal applications and methods of treatment

Publications (1)

Publication Number Publication Date
US20050100564A1 true US20050100564A1 (en) 2005-05-12

Family

ID=34429314

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/772,964 Abandoned US20050100564A1 (en) 2003-11-11 2004-02-04 Controlled release delivery system for nasal applications
US11/560,187 Abandoned US20070149454A1 (en) 2003-11-11 2006-11-15 Controlled Release Delivery System for Nasal Applications and Method of Treatment
US12/796,165 Abandoned US20100311707A1 (en) 2003-11-11 2010-06-08 Controlled release delivery system for nasal applications and methods of treatment
US13/194,853 Expired - Lifetime US8784882B2 (en) 2003-11-11 2011-07-29 Controlled release delivery system for nasal applications and method of treatment
US13/194,928 Expired - Fee Related US8574622B2 (en) 2003-11-11 2011-07-30 Controlled release delivery system for nasal applications
US13/316,494 Expired - Lifetime US8877230B2 (en) 2003-11-11 2011-12-10 Controlled release delivery system for nasal applications

Family Applications After (5)

Application Number Title Priority Date Filing Date
US11/560,187 Abandoned US20070149454A1 (en) 2003-11-11 2006-11-15 Controlled Release Delivery System for Nasal Applications and Method of Treatment
US12/796,165 Abandoned US20100311707A1 (en) 2003-11-11 2010-06-08 Controlled release delivery system for nasal applications and methods of treatment
US13/194,853 Expired - Lifetime US8784882B2 (en) 2003-11-11 2011-07-29 Controlled release delivery system for nasal applications and method of treatment
US13/194,928 Expired - Fee Related US8574622B2 (en) 2003-11-11 2011-07-30 Controlled release delivery system for nasal applications
US13/316,494 Expired - Lifetime US8877230B2 (en) 2003-11-11 2011-12-10 Controlled release delivery system for nasal applications

Country Status (23)

Country Link
US (6) US20050100564A1 (de)
EP (1) EP1530965B1 (de)
JP (1) JP4616270B2 (de)
KR (1) KR100861443B1 (de)
AR (1) AR047722A1 (de)
AT (1) ATE319426T1 (de)
AU (1) AU2004286781B2 (de)
BR (1) BRPI0416370B8 (de)
CA (1) CA2541498C (de)
DE (1) DE60303854T2 (de)
DK (1) DK1530965T3 (de)
ES (1) ES2258694T3 (de)
HR (1) HRP20060147B1 (de)
MY (1) MY131483A (de)
NO (1) NO338665B1 (de)
PL (1) PL219338B1 (de)
PT (1) PT1530965E (de)
RU (1) RU2331423C2 (de)
SA (1) SA04250363B1 (de)
SI (1) SI1530965T1 (de)
TW (1) TWI350176B (de)
WO (1) WO2005044273A1 (de)
ZA (1) ZA200603115B (de)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120009249A1 (en) * 2006-10-04 2012-01-12 Claudia Mattern Controlled release delivery system for nasal application of neurotransmitters
WO2012156820A1 (en) 2011-05-15 2012-11-22 Trimel Pharmaceuticals Corp. Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
WO2012156821A1 (en) 2011-05-13 2012-11-22 Trimel Pharmaceuticals Corp. Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US8574622B2 (en) 2003-11-11 2013-11-05 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal applications
US8609043B2 (en) 2004-12-28 2013-12-17 M & P Patent Aktiengesellschaft Use of a container of an inorganic additive containing plastic material
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US10111888B2 (en) 2011-05-13 2018-10-30 Acerus Biopharma Inc. Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US10668084B2 (en) 2011-05-13 2020-06-02 Acerus Biopharma Inc. Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11234928B2 (en) 2017-11-27 2022-02-01 Aska Pharmaceutical Co., Ltd. Powder preparation for nasal administration
US11903951B2 (en) 2016-06-03 2024-02-20 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ294041B6 (cs) 1996-10-01 2004-09-15 Magotteaux International S.A. Otěruvzdorný díl z kompozitního materiálu
BR0215127B1 (pt) 2001-12-04 2011-12-13 método para produzir partes de desgaste fundida.
EP1750766B1 (de) 2004-05-11 2013-07-03 Emotional Brain B.V. Pharmazeutische Formulierungen und ihre Verwendungen bei der Behandlung von weiblicher sexueller Dysfunktion
EP1790343A1 (de) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US8147980B2 (en) 2006-11-01 2012-04-03 Aia Engineering, Ltd. Wear-resistant metal matrix ceramic composite parts and methods of manufacturing thereof
EP1925307A1 (de) * 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
GB2482868A (en) 2010-08-16 2012-02-22 Franciscus Wilhelmus Henricus Maria Merkus A testosterone liquid spray formulation for oromucosal administration
US20130040922A1 (en) * 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
EA202192397A3 (ru) * 2011-05-16 2022-03-31 Эйсерус Биофарма Инк. Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013169060A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 패혈증 예방 또는 치료용 조성물
ES2691070T3 (es) 2012-05-11 2018-11-23 Kael-Gemvax Co.,Ltd Péptidos antiinflamatorios y composición que comprende los mismos
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20150297733A1 (en) * 2012-11-14 2015-10-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
WO2014083432A2 (en) * 2012-11-14 2014-06-05 Trimel Biopharma Srl Female intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
CA2926183C (en) 2013-10-23 2018-07-03 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
EP3072519B1 (de) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptid mit angiogenesehemmender wirkung und zusammensetzung damit
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
EP3145489A1 (de) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und therapien
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
WO2016033430A1 (en) 2014-08-28 2016-03-03 Board Of Regents, The University Of Texas System Formulations of testosterone and methods of treatment therewith
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102636129B1 (ko) 2015-02-27 2024-02-14 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
EP3318265B1 (de) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptid mit antiviraler wirkung und zusammensetzung damit
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
BR112018067554A2 (pt) * 2016-03-02 2019-03-06 Medcara Pharmaceuticals, Llc formulações de testosterona e métodos de tratamento com as mesmas
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP4272829A3 (de) 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptid mit wirkung zur erhöhung der telomeraseaktivität und telomerextension und zusammensetzung damit
KR20190109452A (ko) 2017-01-20 2019-09-25 엠 이티 피 파마 아게 대기 오염 물질에의 노출 위험을 감소시키기 위한 비강 약학적 조성물
ES2969301T3 (es) 2017-02-02 2024-05-17 Otolanum Ag Composición intranasal que comprende betahistina
CA3087840A1 (en) 2018-01-11 2019-07-18 M et P Pharma AG Treatment of demyelinating diseases
IL277801B2 (en) 2018-04-09 2025-06-01 Katana Pharmaceuticals Inc Oxytocin compositions and methods of use
CA3097090A1 (en) 2018-04-17 2019-10-24 M et P Pharma AG Compositions and methods for intranasal delivery of pregnenolone
AU2019365255B2 (en) 2018-10-26 2025-06-12 Viramal Limited Mucoadhesive gel composition
CN113365635A (zh) * 2018-12-14 2021-09-07 阿克罗斯生物制药公司 睾酮的活性酯衍生物、组合物和其用途
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
US4581225A (en) * 1984-04-25 1986-04-08 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5514673A (en) * 1993-04-07 1996-05-07 Astra Aktiebolag Pharmaceutical composition containing lipophilic drugs
US5645856A (en) * 1994-03-16 1997-07-08 R. P. Scherer Corporation Delivery systems for hydrophobic drugs
US5863554A (en) * 1987-05-22 1999-01-26 Danbiosyst Uk Limited Enhanced uptake drug delivery system
US5897894A (en) * 1997-12-29 1999-04-27 General Mills, Inc. Microwave popcorn with coarse salt crystals and method of preparation
US6432440B1 (en) * 1997-04-18 2002-08-13 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces
US20020136752A1 (en) * 2001-02-14 2002-09-26 Gw Pharmaceuticals Limited Pharmaceutical formulations
US20040005275A1 (en) * 2002-07-03 2004-01-08 Lyfjathroun Hf. Absorption promoting agent
US20070149454A1 (en) * 2003-11-11 2007-06-28 M & P Patent Aktiengesellschaft, C/O Fundationsanstalt Controlled Release Delivery System for Nasal Applications and Method of Treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US431925A (en) * 1890-07-08 Island
DE943792C (de) * 1949-02-18 1956-06-01 Organon Nv Verfahren zur Herstellung von injizierbaren Hormonpraeparaten
GB1032874A (en) 1964-02-13 1966-06-15 Du Pont Stabilized polyoxymethylenes
NL7506407A (nl) * 1975-05-30 1976-12-02 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
NL7510104A (nl) * 1975-08-27 1977-03-01 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
DE2548413A1 (de) * 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US5049387A (en) * 1987-03-09 1991-09-17 Alza Corporation Inducing skin tolerance to a sensitizing drug
JP2543708B2 (ja) * 1987-07-13 1996-10-16 旭化成工業株式会社 難溶性薬物を封入したエマルジョン製剤の製造方法
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5221698A (en) 1991-06-27 1993-06-22 The Regents Of The University Of Michigan Bioactive composition
US5756071A (en) * 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
CA2182577C (en) * 1994-02-04 2002-08-20 Anders Carlsson Lipophilic carrier preparations
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
GB9823246D0 (en) * 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
GB9828861D0 (en) 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
HU229455B1 (en) * 1999-04-01 2013-12-30 Merck Sharp & Dohme Formulation comprising testosteron undecanoate and castor oil
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6583129B1 (en) 1999-06-11 2003-06-24 Watson Pharmaceuticals, Inc. Administration of non-oral androgenic steroids to women
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AU7984200A (en) 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
CA2325106A1 (en) 1999-12-06 2001-06-06 Stanley L. Gore Compositions and methods for intranasal delivery of active agents to the brain
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20020072509A1 (en) 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
WO2002069906A2 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
US6833478B2 (en) 2001-07-13 2004-12-21 Sri International N,N-dinitramide salts as solubilizing agents for biologically active agents
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
IL163981A0 (en) 2002-03-15 2005-12-18 Unimed Pharmaceuticals Inc Androgen pharmaceutical composition and method fortreating depression
US7029657B2 (en) 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
US6958142B2 (en) 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
WO2005065185A2 (en) 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
CA2664427C (en) 2006-10-04 2012-06-05 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
US4581225A (en) * 1984-04-25 1986-04-08 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
US5863554A (en) * 1987-05-22 1999-01-26 Danbiosyst Uk Limited Enhanced uptake drug delivery system
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5514673A (en) * 1993-04-07 1996-05-07 Astra Aktiebolag Pharmaceutical composition containing lipophilic drugs
US5645856A (en) * 1994-03-16 1997-07-08 R. P. Scherer Corporation Delivery systems for hydrophobic drugs
US6432440B1 (en) * 1997-04-18 2002-08-13 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces
US5897894A (en) * 1997-12-29 1999-04-27 General Mills, Inc. Microwave popcorn with coarse salt crystals and method of preparation
US20020136752A1 (en) * 2001-02-14 2002-09-26 Gw Pharmaceuticals Limited Pharmaceutical formulations
US20040005275A1 (en) * 2002-07-03 2004-01-08 Lyfjathroun Hf. Absorption promoting agent
US20070149454A1 (en) * 2003-11-11 2007-06-28 M & P Patent Aktiengesellschaft, C/O Fundationsanstalt Controlled Release Delivery System for Nasal Applications and Method of Treatment

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962394B2 (en) 2003-11-11 2018-05-08 M et P Pharma AG Controlled release delivery system for nasal applications and method of treatment
US8877230B2 (en) 2003-11-11 2014-11-04 Mattern Pharma Ag Controlled release delivery system for nasal applications
US8784882B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and method of treatment
US9238072B2 (en) 2003-11-11 2016-01-19 Mattern Pharma Ag Controlled release delivery system for nasal applications and method of treatment
US8574622B2 (en) 2003-11-11 2013-11-05 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal applications
US9579280B2 (en) 2003-11-11 2017-02-28 Mattern Pharma Ag Controlled release delivery system for nasal applications and method of treatment
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
US8609043B2 (en) 2004-12-28 2013-12-17 M & P Patent Aktiengesellschaft Use of a container of an inorganic additive containing plastic material
US9801834B2 (en) * 2006-10-04 2017-10-31 M et P Pharma AG Controlled release delivery system for nasal application of neurotransmitters
US20160089347A1 (en) * 2006-10-04 2016-03-31 Mattern Pharma Ag Controlled release delivery system for nasal application of neurotransmitters
US9186320B2 (en) * 2006-10-04 2015-11-17 Mattern Pharma Ag Controlled release delivery system for nasal application of neurotransmitters
US20120009249A1 (en) * 2006-10-04 2012-01-12 Claudia Mattern Controlled release delivery system for nasal application of neurotransmitters
US10668084B2 (en) 2011-05-13 2020-06-02 Acerus Biopharma Inc. Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US10111888B2 (en) 2011-05-13 2018-10-30 Acerus Biopharma Inc. Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
WO2012156821A1 (en) 2011-05-13 2012-11-22 Trimel Pharmaceuticals Corp. Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
WO2012156822A1 (en) 2011-05-15 2012-11-22 Trimel Pharmaceuticals Corp. Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
CN110613679A (zh) * 2011-05-15 2019-12-27 埃瑟尔斯生物医药有限公司 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统
WO2012156820A1 (en) 2011-05-15 2012-11-22 Trimel Pharmaceuticals Corp. Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
EP3977982A1 (de) 2011-05-15 2022-04-06 Acerus Biopharma Inc. Kontrollierte freisetzung von nasalen testosterongelen, verfahren und vorgefüllte mehrfachdosisapplikatorsysteme zur pernasalen verabreichung
US11903951B2 (en) 2016-06-03 2024-02-20 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
US11234928B2 (en) 2017-11-27 2022-02-01 Aska Pharmaceutical Co., Ltd. Powder preparation for nasal administration
US11752102B2 (en) 2017-11-27 2023-09-12 Aska Pharmaceutical Co., Ltd. Powder preparation for nasal administration

Also Published As

Publication number Publication date
US20070149454A1 (en) 2007-06-28
US8877230B2 (en) 2014-11-04
JP2007530446A (ja) 2007-11-01
CA2541498C (en) 2009-05-26
NO338665B1 (no) 2016-09-26
PT1530965E (pt) 2006-05-31
ZA200603115B (en) 2007-09-26
DE60303854T2 (de) 2006-08-10
SA04250363B1 (ar) 2013-03-13
BRPI0416370A (pt) 2007-05-22
KR20060109903A (ko) 2006-10-23
NO20062619L (no) 2006-06-07
HRP20060147B1 (hr) 2014-02-14
TWI350176B (en) 2011-10-11
US8574622B2 (en) 2013-11-05
JP4616270B2 (ja) 2011-01-19
US8784882B2 (en) 2014-07-22
PL379867A1 (pl) 2006-11-27
DE60303854D1 (de) 2006-05-04
WO2005044273A8 (en) 2006-08-31
DK1530965T3 (da) 2006-07-17
ES2258694T3 (es) 2006-09-01
EP1530965A1 (de) 2005-05-18
PL219338B1 (pl) 2015-04-30
RU2331423C2 (ru) 2008-08-20
ATE319426T1 (de) 2006-03-15
MY131483A (en) 2007-08-30
US20120058176A1 (en) 2012-03-08
WO2005044273A1 (en) 2005-05-19
SI1530965T1 (sl) 2006-06-30
CA2541498A1 (en) 2005-05-19
BRPI0416370B8 (pt) 2021-05-25
HRP20060147A2 (en) 2006-11-30
AR047722A1 (es) 2006-02-15
BRPI0416370B1 (pt) 2018-09-18
US20120009250A1 (en) 2012-01-12
EP1530965B1 (de) 2006-03-08
US20100311707A1 (en) 2010-12-09
AU2004286781A1 (en) 2005-05-19
KR100861443B1 (ko) 2008-10-02
AU2004286781B2 (en) 2010-06-03
US20120083480A1 (en) 2012-04-05
RU2006120468A (ru) 2007-12-27
TW200515918A (en) 2005-05-16

Similar Documents

Publication Publication Date Title
US8574622B2 (en) Controlled release delivery system for nasal applications
CN101600417B (zh) 用于神经递质的经鼻施用的控制释放递送系统
KR100217258B1 (ko) 경비조성물
US9579280B2 (en) Controlled release delivery system for nasal applications and method of treatment
CN101484138A (zh) 难溶性药用活性成分的纳米乳液和制备该乳液的方法
Bechgaard et al. Intranasal absorption of melatonin in vivo bioavailability study
MXPA06005325A (en) Controlled release delivery system for nasal applications
JPH07165614A (ja) 経鼻組成物及びそれを含有する経鼻製剤
JP2001526194A (ja) 局所的カルバマゼピン製剤及び使用方法
HK1137658B (en) Controlled release delivery system for nasal application of neurotransmitters

Legal Events

Date Code Title Description
AS Assignment

Owner name: MATTERN, UDO, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MATTERN, CLAUDIA;REEL/FRAME:014696/0828

Effective date: 20040203

AS Assignment

Owner name: M & P PATENT AKTIENGESELLSCHAFT, C/O FUNDATIONSANS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MATTERN, UDO;REEL/FRAME:018553/0424

Effective date: 20061108

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: MATTERN PHARMA AG, LIECHTENSTEIN

Free format text: MERGER;ASSIGNOR:M & P PATNT AKTIENGESELLSCHAFT;REEL/FRAME:032291/0349

Effective date: 20140204

AS Assignment

Owner name: MATTERN PHARMA AG, LIECHTENSTEIN

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE TO CORRECT THE ASSIGNOR FROM M & P PATNT AKTIENGESELLSCHAFT TO M & P PATENT AKTIENGESELLSCHAFT PREVIOUSLY RECORDED ON REEL 032291 FRAME 0349. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER EFFECTIVE 02/04/2014;ASSIGNOR:M & P PATENT AKTIENGESELLSCHAFT;REEL/FRAME:032422/0169

Effective date: 20140204

AS Assignment

Owner name: ACERUS PHARMACEUTICALS SRL, BARBADOS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MIDCAP FUNDING V TRUST;REEL/FRAME:047207/0254

Effective date: 20170106

AS Assignment

Owner name: PRECISIOBIOTIX TECHNOLOGIES INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHAGELUX (CANADA), INC.;REEL/FRAME:063307/0577

Effective date: 20230331